Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.

ABSTRACT:

Importance

In recent years, significant progress has been made in the pharmacologic treatment of heart failure (HF) with reduced ejection fraction (HFrEF), but there is still insufficient evidence for drug therapy for HF with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF).

Objective

To compare the outcomes associated with different drug combinations for the treatment of HFpEF and HFmrEF.

Data sources

A search of the PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases was conducted for studies published from inception to October 9, 2021.

Study selection

Randomized clinical trials on the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), angiotensin rec

SUBMITTER: Xiang B 

PROVIDER: S-EPMC9490501 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature